Data from Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival

Autor: Tanja D. de Gruijl, Klaas Hoekman, Epie Boven, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Giuseppe Giaccone, Rik J. Scheper, Henk J. Broxterman, Dinja Oosterhoff, Laura Vroling, Astrid A.M. van der Veldt, Hester van Cruijsen

Purpose: A disturbed myeloid lineage development with abnormally abundant neutrophils and impaired dendritic cell (DC) differentiation may contribute to tumor immune escape. We investigated the effect of sunitinib, a tyrosine kinase inhibitor of fms-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef92c47b977047796352d26cc5cfcae
https://doi.org/10.1158/1078-0432.c.6517093.v1

Data from Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

Autor: Josep Tabernero, Renee Iacona, Alan Swaisland, Paul Elvin, Esther Casado, Paul Hamberg, Duncan I. Jodrell, Herbert I. Hurwitz, Klaas Hoekman, Isabel Chirivella, Erika Martinelli, Andres Cervantes, José Baselga

Purpose: This dose-escalation study evaluated the safety, tolerability, and pharmacokinetics (PK) of the oral Src inhibitor saracatinib (AZD0530) in patients with advanced solid malignancies. Tumor biopsy samples were taken to investigate the effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::059028863b62448b50296c71e9bfcd5c
https://doi.org/10.1158/1078-0432.c.6518903

Abstract P6-10-07: Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study

Autor: Klaas Hoekman, E. van der Wall, H. van Cruijsen, Ajm van den Eertwegh, Paula R. Pohlmann, SM Lougheed, Herbert M. Pinedo, Jan Buter, Jjm van der Hoeven, R Scheper, T.D. de Gruijl, Agm Stam

Publikováno v: Cancer Research. 77:P6-10

This abstract was not presented at the symposium.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37cdf5c25cb716f72e4d568193c0f235
https://doi.org/10.1158/1538-7445.sabcs16-p6-10-07

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

Autor: Renee Iacona, Alan Swaisland, José Baselga, Paul Elvin, Andrés Cervantes, Herbert Hurwitz, Esther Casado, Klaas Hoekman, Duncan I. Jodrell, Erika Martinelli, Josep Tabernero, Paul Hamberg, Isabel Chirivella

Publikováno v: Baselga, J, Cervantes, A, Martinelli, E, Chirivella, I, Hoekman, K, Hurwitz, H I, Jodrell, D I, Hamberg, P, Casado, E, Elvin, P, Swaisland, A, Iacona, R & Tabernero, J 2010, ' Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors ', Clinical Cancer Research, vol. 16, no. 19, pp. 4876-4883 . https://doi.org/10.1158/1078-0432.CCR-10-0748
Clinical Cancer Research, 16(19), 4876-4883. American Association for Cancer Research Inc.

Purpose: This dose-escalation study evaluated the safety, tolerability, and pharmacokinetics (PK) of the oral Src inhibitor saracatinib (AZD0530) in patients with advanced solid malignancies. Tumor biopsy samples were taken to investigate the effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95278ce39f07a387b1010d1da53a477
https://hdl.handle.net/1871/46356

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

Autor: Walter Fiedler, Emile E. Voest, Jan H.M. Schellens, Jane Robertson, Florence Le Maulf, Carla M.L. van Herpen, Anitra Fielding, Johann S. de Bono, Hubert E. Blum, Clemens Unger, Joachim Drevs, Marlies H.G. Langenberg, Klaas Hoekman

Publikováno v: Langenberg, M H G, van Herpen, C M L, De Bono, J, Schellens, J H M, Unger, C, Hoekman, K, Blum, H E, Fiedler, W, Drevs, J, Le Maulf, F, Fielding, A, Robertson, J & Voest, E E 2009, ' Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors ', Journal of Clinical Oncology, vol. 27, no. 36, pp. 6152-6159 . https://doi.org/10.1200/JCO.2009.22.2273
Journal of Clinical Oncology, 27(36), 6152-6159. American Society of Clinical Oncology
Journal of Clinical Oncology, 27, 6152-9
Journal of Clinical Oncology, 27, 36, pp. 6152-9

Purpose Hypertension is a commonly reported adverse effect after administration of vascular endothelial growth factor (VEGF) inhibitors. Cediranib is a highly potent and selective VEGF signaling inhibitor of all three VEGFRs. This study prospectively

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5fc89eb7e1c75a8784428be8c8b58f4
https://doi.org/10.1200/JCO.2009.22.2273